The 2019 novel coronavirus (2019-nCoV), officially named as COVID-19 pandemic by the WHO,...
Lilly starts Phase I trial of antibody therapy for Covid-19
Eli Lilly has started dosing participants in the Phase I clinical trial of antibody therapy LY-CoV555, which is intended to treat Covid-19 infection.
Remdesivir shows clinical improvement in Phase III Covid-19 trial
Gilead Sciences has reported positive top-line data from the Phase III SIMPLE clinical trial of remdesivir in hospitalised patients with moderate Covid-19 pneumonia.
Minerva Neurosciences’ roluperidone fails in Phase III study
Minerva Neurosciences has reported that roluperidone failed to meet endpoints in a Phase III clinical trial for the treatment of negative symptoms in schizophrenia.
Sun Pharma to trial Nafamostat for Covid-19 treatment
Sun Pharmaceutical Industries has secured approval from the Drugs Controller General of India (DCGI) to conduct a clinical trial of pancreatitis drug, Nafamostat Mesilate, to treat Covid-19 patients in the country.
Moderna starts dosing in Phase II Covid-19 vaccine trial
Moderna has started dosing the first participants in all age cohorts of the Phase II clinical trial of its Covid-19 vaccine candidate, mRNA-1273.
UK researchers study anti-inflammatory drug camostat for Covid-19
Researchers at Cancer Research UK and its partners have initiated a clinical trial to study camostat, used to treat inflammation of the pancreas, as a potential therapy against Covid-19.
PureTech to assess LYT-100 for Covid-19 respiratory complications
PureTech Health has plans to conduct a clinical trial to assess its LYT-100 (deupirfenidone) drug candidate to treat serious respiratory complications that persist even after resolution of Covid-19 infection.
Atriva Therapeutics to conduct Phase II Covid-19 trial
Germany-based Atriva Therapeutics is set to conduct a Phase II clinical trial of its oral small molecule, ATR-002, for the treatment of moderate to severe Covid-19 patients requiring hospitalisation.
Aerpio and Quantum Leap to study razuprotafib for ARDS in Covid-19
Aerpio Pharmaceuticals has partnered with Quantum Leap Healthcare Collaborative to assess razuprotafib in the I-SPY COVID trial to treat acute respiratory distress syndrome (ARDS) in adults with moderate to severe Covid-19.
Acadia to combine two Phase III trials of pimavanserin in MDD
Acadia Pharmaceuticals has plans to combine Phase III CLARITY-2 and CLARITY-3 clinical trials of pimavanserin for the adjunctive therapy of major depressive disorder (MDD) into one study.